LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Illumina Inc

Închisă

SectorSănătate

83.64 3.28

Rezumat

Modificarea prețului

24h

Curent

Minim

80

Maxim

84

Indicatori cheie

By Trading Economics

Venit

-56M

131M

Vânzări

-63M

1B

EPS

0.97

Marjă de profit

12.584

Angajați

8,970

EBITDA

55M

284M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+37.47% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-3.4B

13B

Deschiderea anterioară

80.36

Închiderea anterioară

83.64

Sentimentul știrilor

By Acuity

40%

60%

136 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Illumina Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 mar. 2025, 09:18 UTC

Acțiuni populare

Stocks to Watch Tuesday: Tesla, Oracle, Delta, Nvidia -- WSJ

10 mar. 2025, 21:07 UTC

Top știri

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

10 mar. 2025, 20:01 UTC

Top știri

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

4 mar. 2025, 10:56 UTC

Acțiuni populare

Stocks to Watch Tuesday: Illumina, Nvidia, Stellantis -- WSJ

Comparație

Modificare preț

Illumina Inc Așteptări

Obiectiv de preț

By TipRanks

37.47% sus

Prognoză pe 12 luni

Medie 111.21 USD  37.47%

Maxim 185 USD

Minim 75 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIllumina Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

20 ratings

9

Cumpărare

9

Păstrare

2

Vânzare

Scor tehnic

By Trading Central

77.61 / N/ASuport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

136 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.